Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer

Figure 1 Kaplan-Meier estimates. A: Local control rates from the end of magnetic resonance-guided radiotherapy (MRgRT); B: Time from end of MRgRT to distant progression; C: Overall survival rates from end of MRgRT; D: Overall survival rates from diagnosis of metastatic disease. LC: Local control; RT: Radiotherapy; TTDP: Time to distant progression; MRgRT: Magnetic resonance-guided radiotherapy; mOS: Median overall survival.

Figure 2 Kaplan-Meier estimates of overall survival from the start of magnetic resonance-guided radiotherapy, Eastern Cooperative Oncology Group performance status, baseline carbohydrate antigen 19-9 level at the beginning of magnetic resonance-guided radiotherapy, and radiographic response of distant metastases to chemotherapy. A: Stratified by solitary-organ metastases vs multiple-organ metastases; B: Eastern Cooperative Oncology Group performance status (0 vs 1-2); C: Baseline carbohydrate antigen 19-9 level at the beginning of magnetic resonance-guided radiotherapy (< 500 U/mL vs > 500 U/mL); D: Radiographic response of distant metastases to chemotherapy (stable vs uncontrolled). mOS: Median overall survival; ECOG: Eastern Cooperative Oncology Group; CA19-9: Carbohydrate antigen 19-9; RT: Radiotherapy.